- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03611231
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma
August 1, 2018 updated by: Jun Zhu, Peking University
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
Study Overview
Detailed Description
Chidamide,a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral T-cell lymphoma in China.
The aim of this study was to observe the efficacy and safety of Chidamide as Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma
Study Type
Interventional
Enrollment (Anticipated)
43
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jun Zhu, Dr.
- Phone Number: 010-88140650
- Email: dreaming2217@hotmai.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100000
- BEIJING
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with B-NHL,NK/T-NHL and HL were confirmed by histopathology examination had received autologous hematopoietic stem cell transplantation (including secondary transplantation). Transplantation interval was 6-8 weeks before in the study. The first diagnostic risk classification or pre-transplant disease status of each type of lymphoma is as follows: 1)B-NHL: patients who are at high risk according to the corresponding international prognostic index in the first diagnosis(IPI>3 /aa IPI >2 /FLIPI>3); Patients must have received at least one first-line induction therapy but did not achieve CR or had relapse after CR; 2)NK/T-NHL: Including all patients, unlimited risk classification and pre-transplant disease status; 3)HL: Patients must have received at least one first-line induction therapy
- Age 18-70 years, male or female;
- ECOG performance status 0-1;
- Organ function should fit the following : Renal function with serum creatinine < 160μmol/L; Liver function with Total bilirubin ≤2 times of normal maximum, ALT and AST≤3 times of normal maximum. Adequate pulmonary function with forced expiratory volume at one second (FEV1), forced vital capacity (FVC) and diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50% of expected corrected for hemoglobin. Adequate cardiac function with left ventricular ejection fraction ≥ 50%. No symptomatic cardiac disease;
- Blood routine test: absolute neutrophil count ≥1.5×109/L, platelet ≥75×109/L, Hb ≥ 90g/L;
- Life expectancy no less than 3 months;
- Patients willing to sign the Informed Consent Form.
Exclusion Criteria:
- Patients relapsed after ASCT
- Patients with HBsAg positive or HBcAb positive patients also detected HBV-DNA copy number positive;
- Patients with active HCV infection;
- Patients with active HIV infection;
- Patients with uncontrolled cardiovascular and cerebrovascular diseases, coagulopathy, connective tissue disease, severe infectious diseases and others;
- Patients with liver cirrhosis or evidence of liver fibrosis;
- Patients with a QTc longer than 500 ms;
- Patients with mental disorders or those do not have the ability to consent;
- Patients with drug abuse, long term alcoholism that may impact the results of the trial;
- Women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures;
- Non-appropriate patients for the trial according to the judgment of the investigators;
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
chidamide
|
Chidamide 20mg orally BIW.
Treatment cycles are repeated every 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression-free survival(PFS)
Time Frame: up to 2 years
|
Time from treatment until disease progression or death
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
overall survival(OS)
Time Frame: up to 2 years
|
Time from treatment until death from any cause
|
up to 2 years
|
Treatment-related adverse events (AEs)
Time Frame: 2 years
|
Physiological parameter
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 1, 2018
Primary Completion (Anticipated)
December 30, 2020
Study Completion (Anticipated)
December 30, 2022
Study Registration Dates
First Submitted
June 25, 2018
First Submitted That Met QC Criteria
August 1, 2018
First Posted (Actual)
August 2, 2018
Study Record Updates
Last Update Posted (Actual)
August 2, 2018
Last Update Submitted That Met QC Criteria
August 1, 2018
Last Verified
August 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CSIIT-Q06
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Experimental Tumor
-
Sun Yat-sen UniversityUnknown
-
Anwita BiosciencesShanghai Junshi Bioscience Co., Ltd.RecruitingLymphoma | Solid Tumor, Adult | Neoplasm Malignant | Neoplasm, ExperimentalTaiwan
-
University of British ColumbiaOttawa Hospital Research Institute; Government of AlbertaCompleted
-
University of California, San DiegoIndiana University; University of Central Florida; Pacific Institute for Research... and other collaboratorsRecruitingExperimental | ControlUnited States
-
Philipps University Marburg Medical CenterCompletedControl Group | Experimental Group 1 (Video Personal Expert) | Experimental Group 2 (Video Factual Expert)Germany
-
University of OttawaRecruiting
-
Florida State UniversityCompletedExperimental | Placebo ContolUnited States
-
Peking UniversityPeking University International Hospital; Jiangxi Provincial Cancer Hospital; Shandong Tumor HospitalUnknownExperimental TumorChina
-
Universiti Putra MalaysiaEnrolling by invitationExperimental MyastheniaChina
-
Universiti Putra MalaysiaCompletedExperimental MyastheniaChina
Clinical Trials on Chidamide
-
Huiqiang HuangUnknownLymphoma, Extranodal NK-T-Cell | EBV
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Sun Yat-sen UniversityRecruitingTriple Negative Breast CancerChina
-
Sun Yat-sen UniversityUnknown
-
Zhejiang UniversityRecruitingT Lymphoblastic Leukemia/LymphomaChina
-
Sichuan UniversityRecruiting
-
Cancer Institute and Hospital, Chinese Academy...UnknownNatural Killer/T-Cell Lymphoma, Nasal and Nasal-TypeChina
-
Jiangsu HengRui Medicine Co., Ltd.RecruitingRelapsed/Refractory PTCLT With at Least One Line of Prior Systemic TherapyChina
-
Liling ZhangCSPC Ouyi Pharmaceutical Co., Ltd.RecruitingNewly Diagnosed Peripheral T-cell LymphomaChina
-
Dong meiUnknownAdenocystic CarcinomaChina